| Bass Oil Limited (BAS) ORDINARY FULLY PAID |
Energy |
$19 |
Appendix 3Y Mark Lindh
|
23 Jun 2025 9:42AM |
$0.028 |
$0.053 |
risen by
89.29%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$5 |
Options Entitlement Offer Prospectus
|
23 Jun 2025 9:42AM |
$0.125 |
$0.043 |
fallen by
65.60%
|
|
| Prominence Energy Limited (PRM) ORDINARY FULLY PAID |
Energy |
$5 |
Proposed issue of securities - PRM
|
23 Jun 2025 9:42AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
| Prominence Energy Limited (PRM) ORDINARY FULLY PAID |
Energy |
$5 |
Proposed issue of securities - PRM
|
23 Jun 2025 9:42AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
| Prominence Energy Limited (PRM) ORDINARY FULLY PAID |
Energy |
$5 |
Proposed issue of securities - PRM
|
23 Jun 2025 9:42AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$5 |
Underwritten Loyalty Option Entitlement Offer Prospectus
|
23 Jun 2025 9:41AM |
$0.125 |
$0.043 |
fallen by
65.60%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Invion Limited is undertaking an Underwritten Loyalty Option Entitlement Offer.
- Eligible shareholders will receive one new loyalty option for every ten shares held at the record date.
- Loyalty options are exercisable at $0.015 each, expiring on 28 February 2025.
- The offer is fully underwritten to raise approximately $2.27 million before costs.
- Funds raised will support research and development, especially Photosoft technology, and strengthen the balance sheet.
- The prospectus details the terms, risks, and rights associated with the offer and the new options.
- Directors and related parties are participating subject to standard requirements.
- There are specific eligibility criteria for shareholders based on residency and other factors.
- The offer is not being made in jurisdictions outside Australia and New Zealand except as specified.
- The document aims to ensure transparency regarding the use of proceeds and potential dilution effects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prominence Energy Limited (PRM) ORDINARY FULLY PAID |
Energy |
$5 |
PRM to Acquire 100% Interest in Hydrogen and Helium Projects
|
23 Jun 2025 9:41AM |
$0.004 |
$0.002 |
fallen by
50%
|
|
PRM - Price-sensitive ASX Announcement
Full Release
Key Points
- PRM to acquire 100% interest in hydrogen and helium projects via acquisition of H2X Energy Pty Ltd.
- Acquisition includes six exploration permit applications in Queensland targeting hydrogen and helium.
- Binding term sheet signed for the acquisition, subject to due diligence and shareholder approval.
- Transaction positions PRM in the clean energy sector with a focus on hydrogen and helium.
- Exploration strategy and work program outlined for the newly acquired assets.
- Acquisition rationale centered on the growth and demand for clean energy, particularly hydrogen and helium.
- Company to undertake capital raising to fund exploration and development activities.
- Transaction subject to regulatory and ASX approvals, along with customary closing conditions.
- Integration of assets and planning for project development to commence following completion.
- Announcement highlights the strategic value and market opportunity for hydrogen and helium in Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| The Calmer Co International Limited (CCO) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
The Calmer Co Launches Taki Mai Kava Tinctures on Amazon USA
|
23 Jun 2025 9:41AM |
$0.003 |
$0.002 |
fallen by
33.33%
|
|
CCO - Price-sensitive ASX Announcement
Full Release
Key Points
- The Calmer Co International Limited launched Taki Mai Kava Tinctures on Amazon USA.
- The US market is identified as a key growth opportunity for the company.
- Kava tinctures are promoted as natural alternatives for stress and anxiety relief.
- The company is leveraging Amazon’s platform for brand visibility and sales growth.
- There is increasing consumer demand for natural wellness and relaxation products.
- The launch is expected to have a positive impact on sales and brand recognition.
- The company plans to expand similar product launches to other international markets.
- Leadership views this move as an important milestone in US market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trigg Minerals Limited (TMG) ORDINARY FULLY PAID |
Materials |
- |
ADVANCING STUDIES FOR NEAR TERM EXTRACTION & NEW EXTENSIONS
|
23 Jun 2025 9:41AM |
$0.085 |
$0.120 |
risen by
41.18%
|
|
TMG - Price-sensitive ASX Announcement
Full Release
Key Points
- Trigg Minerals Limited is progressing technical studies at the Lake Throssell SOP Project.
- Advancements are being made toward near-term extraction and defining new resource extensions.
- Pilot brine extraction and test work are being conducted to optimize production processes.
- Recent exploration has identified additional SOP-brine resources and expanded known mineralized zones.
- The company is focused on de-risking the project and improving project economics.
- Stakeholder engagement and environmental permitting efforts are ongoing.
- Lake Throssell is positioned as a potential major SOP supplier for domestic and international markets.
- The update provides details on resource upgrades, technical study milestones, and ongoing project development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$277 |
Weekly Estimated NTA as at 20 June 2025
|
23 Jun 2025 9:40AM |
$1.065 |
$0.880 |
fallen by
17.37%
|
|
| Russell Invest Aust Select Corp Bond ETF (RCB) |
Financials |
$343 |
Dividend/Distribution - RCB
|
23 Jun 2025 9:40AM |
$20.490 |
$19.900 |
fallen by
2.88%
|
|
| Russell Invest Aust Semi-Govt Bond ETF (RSM) |
Financials |
$61 |
Dividend/Distribution - RSM
|
23 Jun 2025 9:38AM |
$21.040 |
$20.600 |
fallen by
2.09%
|
|
| Russell Invest Aust Govt Bond ETF (RGB) |
Financials |
$272 |
Dividend/Distribution - RGB
|
23 Jun 2025 9:37AM |
$19.510 |
$18.910 |
fallen by
3.08%
|
|
| Duxton Water Limited (D2O) ORDINARY FULLY PAID |
Utilities |
- |
Extension of On-Market Share Buyback
|
23 Jun 2025 9:37AM |
$1.520 |
$1.530 |
risen by
0.66%
|
|
| Mirrabooka Investments Limited (MIR) ORDINARY FULLY PAID |
Financials |
$546 |
Weekly Estimated NTA as at 20 June 2025
|
23 Jun 2025 9:36AM |
$3.250 |
$2.440 |
fallen by
24.92%
|
|
| Mighty Kingdom Limited (MKL) ORDINARY FULLY PAID |
Communication Services |
- |
Trading Halt
|
23 Jun 2025 9:36AM |
$0.014 |
$0.165 |
risen by
1,078.57%
|
|
MKL - Price-sensitive ASX Announcement
Full Release
Key Points
- Mighty Kingdom Limited (ASX:MKL) requested a trading halt effective 2 May 2023.
- The trading halt is pending an announcement regarding a material transaction.
- The halt ensures full and equal access to relevant information for all investors.
- The trading halt will remain until the earlier of a further announcement or the start of trading on 4 May 2023.
- The company confirms compliance with ASX Listing Rule 17.1 regarding the trading halt request.
- The announcement aims to prevent trading on an uninformed basis.
- MKL's Board authorized the request and communication with the ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| West Wits Mining Limited (WWI) ORDINARY FULLY PAID |
Materials |
$204 |
WWI Commences Key Work Streams
|
23 Jun 2025 9:35AM |
$0.021 |
$0.470 |
risen by
2,138.10%
|
|
| Russell Invest Aust Responsible Inv ETF (RARI) |
Financials |
$430 |
Dividend/Distribution - RARI
|
23 Jun 2025 9:35AM |
$31.180 |
$29.960 |
fallen by
3.91%
|
|
| Finder Energy Holdings Limited (FDR) ORDINARY FULLY PAID |
Energy |
$158 |
Corporate Presentation
|
23 Jun 2025 9:35AM |
$0.091 |
$0.285 |
risen by
213.19%
|
|
FDR - Price-sensitive ASX Announcement
Full Release
Key Points
- Finder Energy Holdings Limited is focused on oil and gas exploration in Australia and the North Sea.
- The company’s portfolio includes high-impact exploration projects and farm-out opportunities.
- Finder’s strategy is to grow through exploration success and value-adding partnerships with major oil and gas companies.
- The company highlights multiple prospects with technical advantages and near-term drilling plans.
- Finder emphasizes prudent financial management and maintaining a strong balance sheet.
- The presentation provides details on key projects, resource estimates, and exploration timelines.
- Market analysis suggests sustained demand for oil and gas, supporting the company’s growth outlook.
- ESG principles are integrated into operational practices and strategic decision-making.
- The management team has significant industry experience and a track record in exploration and value creation.
- Finder is committed to delivering shareholder value through disciplined exploration and strategic partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AIC Mines Limited (A1M) ORDINARY FULLY PAID |
Materials |
$598 |
Conference Call Notification - Expansion and Funding Update
|
23 Jun 2025 9:35AM |
$0.330 |
$0.750 |
risen by
127.27%
|
|
| Jayride Group Limited (JAY) ORDINARY FULLY PAID |
Industrials |
$9 |
Jayride to Launch SaaS Ground Transportation Platform
|
23 Jun 2025 9:34AM |
$0.001 |
$0.006 |
risen by
500%
|
|
JAY - Price-sensitive ASX Announcement
Full Release
Key Points
- Jayride Group Limited (JAY) is launching a new SaaS Ground Transportation Platform.
- The platform targets ground transport companies to manage operations digitally.
- Travel sellers and online agencies gain easier access to ground transport inventory.
- The SaaS platform integrates with various distribution channels and travel partners.
- Jayride is expanding beyond its marketplace model to a SaaS business model.
- The initiative addresses digital transformation in the fragmented ground transport sector.
- Expected benefits include additional recurring revenue and global partnership growth.
- The launch strengthens Jayride's position in the ground transportation technology space.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Duxton Water Limited (D2O) ORDINARY FULLY PAID |
Utilities |
- |
Update - Notification of buy-back - D2O
|
23 Jun 2025 9:34AM |
$1.520 |
$1.530 |
risen by
0.66%
|
|
| Russell Invest High Div Aust Shares ETF (RDV) |
Financials |
$340 |
Dividend/Distribution - RDV
|
23 Jun 2025 9:34AM |
$33.370 |
$34.420 |
risen by
3.15%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$86 |
Application for quotation of securities - ALA
|
23 Jun 2025 9:34AM |
$0.096 |
$0.071 |
fallen by
26.04%
|
|
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
- |
Binge Eating Disorder Trial receives Human Ethics approval
|
23 Jun 2025 9:33AM |
$0.031 |
$0.034 |
risen by
9.68%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Tryptamine Therapeutics Limited (TYP) received HREC approval for a Phase 2 clinical trial using psilocybin-based therapy for Binge Eating Disorder (BED).
- The Phase 2 trial will be conducted at the Monarch Research Institute in Melbourne, Australia.
- The trial will use a randomized, double-blind, placebo-controlled design to assess safety and efficacy.
- Participant recruitment will begin immediately following HREC approval.
- There is a significant unmet medical need for effective BED treatments.
- The trial will evaluate TYP’s proprietary psilocybin-assisted therapy in adults diagnosed with BED.
- Experienced clinicians and researchers will contribute to the trial’s execution and oversight.
- Ethics approval marks a key milestone for TYP’s clinical development program.
- The announcement provides background on BED prevalence and the limitations of current treatment options.
- TYP aims to contribute to the growing body of evidence supporting psychedelic-assisted therapies for mental health conditions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.